NanoViricides is trading 6.00% lower at $1.41, with no clear company-specific announcement explaining the September 29 decline. - The company announced on September 28 that enrollment and dosing began in its Phase II NV-387 Ebola trial; available reporting does not link the development to the decline. - Broader markets are weaker, but the supplied index moves do not establish a direct cause for the stock’s decline.